HRP20191227T1 - Derivat 4-(3-pirazolilamino)benzimidazola kao inhibitor jak1, namijenjen liječenju raka - Google Patents
Derivat 4-(3-pirazolilamino)benzimidazola kao inhibitor jak1, namijenjen liječenju raka Download PDFInfo
- Publication number
- HRP20191227T1 HRP20191227T1 HRP20191227TT HRP20191227T HRP20191227T1 HR P20191227 T1 HRP20191227 T1 HR P20191227T1 HR P20191227T T HRP20191227T T HR P20191227TT HR P20191227 T HRP20191227 T HR P20191227T HR P20191227 T1 HRP20191227 T1 HR P20191227T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- salt
- cancer
- pharmaceutically acceptable
- use according
- Prior art date
Links
- 229940116839 Janus kinase 1 inhibitor Drugs 0.000 title 1
- LVYDVMYMBUCOMX-UHFFFAOYSA-N N-(1H-pyrazol-5-yl)-1H-benzimidazol-4-amine Chemical class N1N=C(C=C1)NC1=CC=CC=2N=CNC=21 LVYDVMYMBUCOMX-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010023774 Large cell lung cancer Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000009956 adenocarcinoma Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 201000009546 lung large cell carcinoma Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (12)
1. Spoj, naznačen time što je spoj Formule I:
,
ili njegova farmaceutski prihvatljiva sol.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što se spoj bira iz skupine koju čine:
,
ili njegova farmaceutski prihvatljiva sol, i
,
ili njegova farmaceutski prihvatljiva sol.
3. Spoj u skladu s patentnim zahtjevom 2, naznačen time što je
,
ili njegova farmaceutski prihvatljiva sol.
4. Spoj u skladu s patentnim zahtjevom 2, naznačen time što je
.
5. Farmaceutski pripravak, naznačen time što sadrži spoj, ili sol, u skladu s bilo kojim od patentnih zahtjeva 1-4, kao i farmaceutski prihvatljivu podlogu, razrjeđivač ili pomoćnu tvar.
6. Spoj, ili sol, u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačen time što je namijenjen upotrebi u terapiji.
7. Spoj, ili sol, u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačen time što je namijenjen upotrebi u liječenju raka.
8. Spoj, ili sol, namijenjen upotrebi u skladu s patentnim zahtjevom 7, naznačen time što se rak bira iz skupine koju čine rak pluća, uključujući rak velikih stanica pluća i plućni adenokarcinom, adenokarcinom, hepatocelularni karcinom, uključujući azijski hepatocelularni karcinom, kolorektalni rak, rak dojke, te leukemija, uključujući akutnu lomfocitnu leukemiju.
9. Spoj, ili sol, namijenjen upotrebi u skladu s patentnim zahtjevom 8, naznačen time što je rak rak velikih stanica pluća.
10. Spoj, ili sol, namijenjen upotrebi u skladu s patentnim zahtjevom 8, naznačen time što je rak plućni adenokarcinom.
11. Spoj, ili sol, namijenjen upotrebi u skladu s patentnim zahtjevom 8, naznačen time što je rak rak dojke.
12. Spoj, ili sol, namijenjen upotrebi u skladu s patentnim zahtjevom 8, naznačen time što je rak azijski hepatocelularni karcinom.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562200684P | 2015-08-04 | 2015-08-04 | |
| PCT/US2016/044410 WO2017023672A1 (en) | 2015-08-04 | 2016-07-28 | 4-(3-pyrazolylamino)-benzimidazole compounds and their use as jak1 inhibitors |
| EP16750326.7A EP3331873B1 (en) | 2015-08-04 | 2016-07-28 | A 4-(3-pyrazolylamino)-benzimidazole derivative as jak1 inhibitor for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191227T1 true HRP20191227T1 (hr) | 2019-10-18 |
Family
ID=56618268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191227TT HRP20191227T1 (hr) | 2015-08-04 | 2019-07-08 | Derivat 4-(3-pirazolilamino)benzimidazola kao inhibitor jak1, namijenjen liječenju raka |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9556153B1 (hr) |
| EP (1) | EP3331873B1 (hr) |
| JP (1) | JP6470869B2 (hr) |
| KR (1) | KR102032792B1 (hr) |
| CN (1) | CN108026076B (hr) |
| AR (1) | AR105400A1 (hr) |
| AU (1) | AU2016302748B2 (hr) |
| BR (1) | BR112017028240B1 (hr) |
| CA (1) | CA2990471C (hr) |
| CY (1) | CY1121909T1 (hr) |
| DK (1) | DK3331873T3 (hr) |
| EA (1) | EA033572B1 (hr) |
| ES (1) | ES2743499T3 (hr) |
| HR (1) | HRP20191227T1 (hr) |
| HU (1) | HUE047037T2 (hr) |
| LT (1) | LT3331873T (hr) |
| MA (1) | MA44383B1 (hr) |
| MD (1) | MD3331873T2 (hr) |
| ME (1) | ME03451B (hr) |
| MX (1) | MX2018001306A (hr) |
| NZ (1) | NZ738247A (hr) |
| PL (1) | PL3331873T3 (hr) |
| PT (1) | PT3331873T (hr) |
| RS (1) | RS58974B1 (hr) |
| SI (1) | SI3331873T1 (hr) |
| TW (1) | TW201718555A (hr) |
| WO (1) | WO2017023672A1 (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10323019B2 (en) | 2016-07-14 | 2019-06-18 | Eli Lilly And Company | Pyrazolylaminobenzimidazole derivatives as JAK inhibitors |
| GB201717260D0 (en) * | 2017-10-20 | 2017-12-06 | Galapagos Nv | Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013025628A1 (en) * | 2011-08-15 | 2013-02-21 | Ligand Pharmaceuticals Incorporated | Janus kinase inhibitor compounds and methods |
| CA2871659C (en) * | 2012-06-14 | 2017-04-04 | Eli Lilly And Company | Inhibitor of jak1 and jak2 |
| GB201401086D0 (en) * | 2014-01-23 | 2014-03-12 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
-
2016
- 2016-07-20 AR ARP160102192A patent/AR105400A1/es unknown
- 2016-07-21 TW TW105123089A patent/TW201718555A/zh unknown
- 2016-07-28 ME MEP-2019-196A patent/ME03451B/me unknown
- 2016-07-28 US US15/221,649 patent/US9556153B1/en active Active
- 2016-07-28 KR KR1020187003079A patent/KR102032792B1/ko active IP Right Grant
- 2016-07-28 EA EA201792676A patent/EA033572B1/ru not_active IP Right Cessation
- 2016-07-28 BR BR112017028240-2A patent/BR112017028240B1/pt active IP Right Grant
- 2016-07-28 SI SI201630314T patent/SI3331873T1/sl unknown
- 2016-07-28 JP JP2018502720A patent/JP6470869B2/ja active Active
- 2016-07-28 CN CN201680045255.7A patent/CN108026076B/zh active Active
- 2016-07-28 DK DK16750326.7T patent/DK3331873T3/da active
- 2016-07-28 PL PL16750326T patent/PL3331873T3/pl unknown
- 2016-07-28 WO PCT/US2016/044410 patent/WO2017023672A1/en active Application Filing
- 2016-07-28 PT PT16750326T patent/PT3331873T/pt unknown
- 2016-07-28 MD MDE20180584 patent/MD3331873T2/ro unknown
- 2016-07-28 EP EP16750326.7A patent/EP3331873B1/en active Active
- 2016-07-28 CA CA2990471A patent/CA2990471C/en active Active
- 2016-07-28 MA MA44383A patent/MA44383B1/fr unknown
- 2016-07-28 RS RS20190876A patent/RS58974B1/sr unknown
- 2016-07-28 ES ES16750326T patent/ES2743499T3/es active Active
- 2016-07-28 LT LTEP16750326.7T patent/LT3331873T/lt unknown
- 2016-07-28 NZ NZ738247A patent/NZ738247A/en unknown
- 2016-07-28 AU AU2016302748A patent/AU2016302748B2/en active Active
- 2016-07-28 HU HUE16750326A patent/HUE047037T2/hu unknown
- 2016-07-28 MX MX2018001306A patent/MX2018001306A/es active IP Right Grant
-
2019
- 2019-07-08 HR HRP20191227TT patent/HRP20191227T1/hr unknown
- 2019-08-16 CY CY20191100882T patent/CY1121909T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210212T1 (hr) | Triciklični spoj kao antikancerogeni agensi | |
| CY1121694T1 (el) | Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4 | |
| RS54873B1 (sr) | Policiklična-karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba | |
| HRP20171151T1 (hr) | Inhibitori cdc7 | |
| PH12017500276A1 (en) | Aminopyrimidinyl compounds as jak inhibitors | |
| AR094918A1 (es) | Compuestos de tetrahidropirrolotiazina como inhibidores de bace | |
| JP2015078230A5 (hr) | ||
| AR102977A1 (es) | Inhibidores de erk | |
| SA515360469B1 (ar) | مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها | |
| EA201792116A1 (ru) | Ингибитор янус-киназы | |
| JP2016533366A5 (hr) | ||
| MX2015012432A (es) | Inhibidores piridinicos de la cinasa cdk9. | |
| EA201600204A1 (ru) | Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли | |
| JP2017537066A5 (hr) | ||
| EA201591913A1 (ru) | Ингибиторы протеинкиназы | |
| RS54492B1 (en) | KINASE INHIBITOR REGULATING THE SIGNAL PATH OF APOPTOSIS | |
| EA201591301A1 (ru) | Новые пиримидиновые и пиридиновые соединения и их применение | |
| HRP20201681T1 (hr) | Inhibitor aurora a kinaze | |
| GEP20186910B (en) | 1,2-substituted cyclopentanes as orexin receptor antagonists | |
| EA201600434A1 (ru) | Применение производных бензимидазолпролина | |
| CY1122077T1 (el) | Νεα δακτυλιωμενα φαινοξυακεταμιδια | |
| MX2018002006A (es) | Benzamidas apareadas novedosas. | |
| HRP20191227T1 (hr) | Derivat 4-(3-pirazolilamino)benzimidazola kao inhibitor jak1, namijenjen liječenju raka | |
| EA201591649A1 (ru) | Составы с органическими соединениями | |
| EA201700356A1 (ru) | Новые циклопропанбензофуранилпиридопиразиндионы |